Who Gets May-Thurner Syndrome?
May-Thurner syndrome is most commonly diagnosed in women between the ages of 18 and 50, though it can affect men as well. It is frequently underdiagnosed because its symptoms — left-leg swelling, DVT, and varicose veins — overlap with other venous conditions. The true prevalence is estimated at 20–30% of the general population having some degree of iliac vein compression, though only a subset develop clinically significant disease.
May-Thurner Syndrome Symptoms
The hallmark presentation is left leg swelling, pain, and heaviness that is asymmetric — meaning the right leg is unaffected. Many patients with May-Thurner are diagnosed after developing a left-sided DVT, often without a clear provoking cause. Other symptoms include prominent varicose veins of the left leg, pelvic pain or heaviness (due to associated pelvic venous congestion), and chronic venous insufficiency changes.
Diagnosing May-Thurner Syndrome in Sarasota & Bradenton
Diagnosis begins with duplex ultrasound to evaluate the venous system and assess for DVT. When May-Thurner is suspected, cross-sectional imaging — CT venography or MRI venography — is used to visualize the iliac vein anatomy and quantify the degree of compression. In some cases, intravascular ultrasound (IVUS) performed at the time of intervention provides the most accurate assessment of vein narrowing.
May-Thurner Treatment: Venous Stenting
Definitive treatment for May-Thurner syndrome is catheter-based venous stenting. A self-expanding stent is placed across the compressed iliac vein segment, restoring normal lumen diameter and venous outflow. In patients who present with acute DVT, catheter-directed thrombolysis or mechanical thrombectomy is first performed to clear the clot before stenting. Most patients experience dramatic improvement in leg swelling and symptoms after successful stenting.
The procedure is performed under conscious sedation, typically requiring a short hospital observation period. Long-term anticoagulation is maintained after stenting to prevent in-stent thrombosis, with the duration determined individually.